Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDOV-SAFE in advanced solid tumors
NCT06346041Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IDOV-Safe in solid tumor (advanced stage), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose Limiting Toxicities at 21 days, Incidence of adverse events and severe adverse events at 85 days and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
IDOV-Safe
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06346041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06346041.